altRx
altRx names OpenLoop and several potential pharmacies for compounded GLP-1 injections. A June 2026 FDA warning and inconsistent descriptions of outcome evidence warrant specific clinical questions.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
Review the FDA findings and resolve the evidence claims before considering the program. Named partners and current disclaimers do not establish regulatory resolution or the suitability of a compounded preparation.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
FDA warning letter on record: Letter 728236 · June 2026
altRx markets compounded semaglutide and tirzepatide as injections. Current policies separate its marketing and administrative role from the OpenLoop platform and independent clinical practices. The FDA’s June 2026 letter identifies Trinity HealthCare Supply, LLC dba altRx for the same website.
What altRx prescribes, by goal
Weight
- SemaglutideFDA-approved
- Injection (compounded)Price not published
- TirzepatideFDA-approved
- Injection (compounded)Price not published
The current pages explicitly describe weekly subcutaneous compounded injections. Obtain the prescription’s concentration, dose and clinical rationale. A protocol resembling an approved brand does not establish that the compounded product has the same trial evidence or approval.
Who prescribes
A licensed clinician
The policies identify the OpenLoop Healthcare Partners network rather than a practitioner assigned to every patient. Product FAQs list possible pharmacies including RedRock, Health Warehouse, Precision Medicine and Triad Rx. Confirm the actual medical practice, clinician and dispensing location instead of assuming every listed partner handles each order.
The product FAQ permits live video or asynchronous professional review, depending on clinical and state requirements. Ongoing care-team support is described, but a guaranteed appointment frequency and response time for the treating practitioner are not established. Ask how dose changes and significant side effects are reassessed.
Are labs required?
Testing inclusion varies and requires product-specific confirmation
The subscription policy says laboratory services may be included where applicable, without establishing a universal patient-testing allowance or cost.
Ready to start with altRx?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
FDA warning 728236, issued June 8, 2026, concerns misleading compounder identity and FDA approval or clinical-evidence implications after a May website review. It is not a facility sterility finding. Current disclaimers do not establish FDA closeout. The product pages describe clinical-study support, while their footer says reported outcomes are self-reported member observations rather than trial data. Some testimonials are paid endorsements. Ask which evidence supports the exact preparation and how outcomes were collected, rather than blending those different sources.
How it bills
The product headers show $89 monthly for semaglutide and $149 for tirzepatide. A dashboard illustration also mentions a three-month subscription, without settling which commitment applies to the displayed amount. Confirm the actual selected term and collection. The bundled program includes clinical and platform components, with shipping described on the product pages. Payment can become nonrefundable immediately, except for limited medical-disqualification treatment. Clarify both the clinical and financial plan before proceeding.
For and against
- For: Clinical network explicitly identified
- For: Potential pharmacies listed
- For: Compounded route and consent described
- Against: Direct FDA marketing warning
- Against: Outcome evidence described inconsistently
- Against: Selected plan and testing allowance unresolved
The evidence behind what it sells
Right for
Someone who will examine the regulatory record, preparation-specific evidence and actual clinical assignment before making a decision.
Look elsewhere if
Someone treating a current disclaimer, partner list or outcome testimonial as proof of agency resolution or product-specific effectiveness.
Other sellers for weight
Vita Bella
Also prescribes Semaglutide, Tirzepatide.
Ark Health
Also prescribes Semaglutide, Tirzepatide.
TrueMe
Also prescribes Semaglutide, Tirzepatide.
altRx
Frequently asked questions
- Does the warning establish a contaminated shipment?
- Its cited findings concern website and labeling representations, not a determination that a particular patient shipment was contaminated.
- Does the current footer prove FDA resolution?
- No. A changed public statement is not an agency closeout.
- Are member observations the same as a clinical trial?
- No. Their collection, controls and evidentiary limits differ.
Sources
- Current semaglutide route, figures, evidence and pharmacy FAQ
- Current tirzepatide route and figure
- OpenLoop and bundled financial roles
- Clinical consent and outcome-data disclosure
- Payment finality, notice and exception terms
- Direct June8,2026 FDA warning and precise findings
See what altRx prescribes today
altRx sets its own prices, plans and the states it serves. Check them before you start.